US biotech Biogen has announced positive results from the Phase II part of the AMETHYST Phase II/III study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE).
Otsuka Pharmaceutical Development & Commercialization, a subsidiary of Japan’s Otsuka, announced new analyses from the Phase III VISIONARY trial evaluating Voyxact (sibeprenlimab-szsi) in adults with ...
German family-owned drugmaker Grünenthal, a global leader in pain management and research, has published 2025 financial ...
Singapore-based biotech Prestige Biopharma has reported positive Phase III results for its Avastin (bevacizumab) biosimilar ...
San Diego, USA-based late-stage biotech ADARx Pharmaceuticals announced the appointment of Ryan Fisk as chief financial officer and chief business officer. In this role, he will be responsible for ...
German family-owned pharma major Boehringer Ingelheim today reported financial results, showing that group sales rose by 7.3% ...
The US Food and Drug Administration is requiring new label warnings for widely used Parkinson’s therapies combining levodopa ...
Progressive pulmonary fibrosis (PPF) describes a phenotype of non-idiopathic pulmonary fibrosis (IPF) interstitial lung ...
USA-based Oryon Cell Therapies, a biotech developing autologous neuron replacement medicines for Parkinson's disease and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results